Fri, Oct 31, 2014, 6:19 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Gilead Sciences Inc. Message Board

  • pkornie@sbcglobal.net pkornie Mar 6, 2012 7:13 PM Flag

    Re: What an ECCELLENT blead!

    .(___Q___).

    ______________...._______________________...._________________________________________..________________________. XXX

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • pkornie@sbcglobal.net pkornie Mar 7, 2012 11:10 PM Flag

      << hffp://aac.asm.org/content/54/8/3187 >>

      << http://aac.asm.org/content/54/8/3187 >>

      << PSI-7851, a Pronucleotide of β-d-2′-Deoxy-2′-Fluoro-2′-C ...aac.asm.org/content/54/8/3187.figures-onlyYou +1'd this publicly. Undo
      PSI-6206 is the 2′-F-2′-C-methyluridine nucleoside analog. PSI-7411 is the monophosphate of PSI-6206. PSI-7851 is the pronucleotide of PSI-7411.
      >>
      <<
      o.

      .

      <<
      Today's Calls
      Call Details
      Gilead Sciences Quad Study 102 Results Conference Call
      Scheduled to start Wed, Mar 7, 2012, 4:30 pm Eastern
      About Gilead Sciences Inc (NasdaqGS:GILD) Other Calls
      Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Truvada, Atripla, Viread, and Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat serious invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa that is used for the treatment of chronic angina; Vistide, an antiviral medication that targets cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company’s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular age-related macular degeneration; and Lexiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Gilead Sciences’ products under the Phase III clinical trials consist of Ambrisentan, an oral endothelin receptor antagonist for the treatment of idiopathic pulmonary fibrosis and pulmonary hypertension; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; and combination of tenofovir disoproxil fumarate, emtricitabine, and TMC278 for the treatment of HIV/AIDS in treatment-naive patients. The company’s Phase II clinical trials products comprise Aztreonam, Cicletanine, Cobicistat, combination of elvitegravir, cobicistat, and Truvada, GS 9190, GS 9310/11, and GS 9450, as well as Ranolazine that is preparing for Phase II clinical trials. Its Phase I clinical trials products include GS 6201, GS 9256, GS 9411, and GS 9667. The company was founded in 1987 and is headquartered in Foster City, California.
      >>

      o.

      .

      Sentiment : Strong Buy

      o.

      .

      Sentiment : Strong Buy

    • pkornie@sbcglobal.net pkornie Mar 6, 2012 7:19 PM Flag

      <<
      Today's Calls
      Call Details
      Gilead Sciences Quad Study 102 Results Conference Call
      Scheduled to start Wed, Mar 7, 2012, 4:30 pm Eastern
      Check back at the scheduled start time for
      the audio link to appear in this spot.
      Add This Event To Your Yahoo! Calendar






      About Gilead Sciences Inc (NasdaqGS:GILD) Other Calls
      Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Truvada, Atripla, Viread, and Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat serious invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa that is used for the treatment of chronic angina; Vistide, an antiviral medication that targets cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company’s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular age-related macular degeneration; and Lexiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Gilead Sciences’ products under the Phase III clinical trials consist of Ambrisentan, an oral endothelin receptor antagonist for the treatment of idiopathic pulmonary fibrosis and pulmonary hypertension; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; and combination of tenofovir disoproxil fumarate, emtricitabine, and TMC278 for the treatment of HIV/AIDS in treatment-naive patients. The company’s Phase II clinical trials products comprise Aztreonam, Cicletanine, Cobicistat, combination of elvitegravir, cobicistat, and Truvada, GS 9190, GS 9310/11, and GS 9450, as well as Ranolazine that is preparing for Phase II clinical trials. Its Phase I clinical trials products include GS 6201, GS 9256, GS 9411, and GS 9667. The company was founded in 1987 and is headquartered in Foster City, California.
      >>

      .(___Q___).

      _______...______________..____________________________..________________________. XXX

      Sentiment : Strong Buy

      • 2 Replies to pkornie
      • pkornie@sbcglobal.net pkornie Mar 7, 2012 10:37 AM Flag

        IamFineW/GILDY.
        When'sDaSp.Susan.

        << hffp://finance.yahoo.com/q/ta?s=GILD&t=my&l=on&z=l&q=l&p=&a=&c=TLON.OB >>
        TurnTheFF'UpSideDWN.

        <<
        Today's Calls
        Call Details
        Gilead Sciences Quad Study 102 Results Conference Call
        Scheduled to start Wed, Mar 7, 2012, 4:30 pm Eastern
        Check back at the scheduled start time for
        the audio link to appear in this spot.
        Add This Event To Your Yahoo! Calendar






        About Gilead Sciences Inc (NasdaqGS:GILD) Other Calls
        Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Truvada, Atripla, Viread, and Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat serious invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa that is used for the treatment of chronic angina; Vistide, an antiviral medication that targets cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company’s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular age-related macular degeneration; and Lexiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Gilead Sciences’ products under the Phase III clinical trials consist of Ambrisentan, an oral endothelin receptor antagonist for the treatment of idiopathic pulmonary fibrosis and pulmonary hypertension; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; and combination of tenofovir disoproxil fumarate, emtricitabine, and TMC278 for the treatment of HIV/AIDS in treatment-naive patients. The company’s Phase II clinical trials products comprise Aztreonam, Cicletanine, Cobicistat, combination of elvitegravir, cobicistat, and Truvada, GS 9190, GS 9310/11, and GS 9450, as well as Ranolazine that is preparing for Phase II clinical trials. Its Phase I clinical trials products include GS 6201, GS 9256, GS 9411, and GS 9667. The company was founded in 1987 and is headquartered in Foster City, California.
        >>

        .(___Q___).

        _______...______________..____________________________..________________________. XXX

        Sentiment : Strong Buy

        Sentiment : Strong Buy

      • GILD will bounce back soon. But don't forget the next great FDA play -TLON.. has ODAC panel on Mar21. Tiny volume, high prob positive review...see below for abstract.

        Talon Therapeutics, Inc. (TLON.OB) is trading at close to $1 per share. This stock has all the stars lining up for it now, and is very likely to produce explosive gains. This company received a large investment from Warburg Pincus several months ago. Warburg is a highly respected investment firm with expertise in life sciences and biotech companies. This company changed its name from Hana Biosciences to Talon Therapeutics no long ago. Just before this name change, Zacks Investment Research issued a very bullish report on this company and laid out a case for this stock to be trading for about $5 per share in the future. Talon has received orphan drug and fast track designations for Marqibo for the treatment of adult ALL (acute lymphoblastic leukemia) from the U.S. Food and Drug Administration. Marqibo has also received orphan drug designation in adult leukemia from the European Medicines Evaluation Agency.

 
GILD
112.00-2.22(-1.94%)Oct 31 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.